Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Jubilant Pharmova's Sloan Ratio for the quarter that ended in Dec. 2024 was 0.00%.
As of Dec. 2024, Jubilant Pharmova has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Jubilant Pharmova Sloan Ratio % Historical Data
The historical data trend for Jubilant Pharmova's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Jubilant Pharmova's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Jubilant Pharmova's Sloan Ratio for the fiscal year that ended in Mar. 2024 is calculated as
Jubilant Pharmova's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was -586 (Mar. 2024 ) + 4821 (Jun. 2024 ) + 1028 (Sep. 2024 ) + 1009 (Dec. 2024 ) = ₹6,272 Mil.
Jubilant Pharmova's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) + 0 (Dec. 2024 ) = ₹0 Mil.
Jubilant Pharmova's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) + 0 (Dec. 2024 ) = ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (NSE:JUBLPHARMA) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2024, Jubilant Pharmova has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Jubilant Pharmova Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Jubilant Pharmova's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:JUBLPHARMA has been successfully added to your 